BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 54 resultados LastUpdate Última actualización 22/02/2020 [16:48:00] pdf PDF

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days

Página1 de 3 nextPage   por página


Methods For The Treatment Of Neurodegeneration

NºPublicación: US2020055921A1 20/02/2020

Solicitante:

MOMENTA PHARMACEUTICALS INC [US]

ES_2708759_T3

Resumen de: US2020055921A1

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

traducir

BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS

NºPublicación: US2020057079A1 20/02/2020

Solicitante:

MCBI INC [JP]

ES_2617918_T3

Resumen de: US2020057079A1

Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

traducir

HUMANIZED ANTIBODY

NºPublicación: US2020055928A1 20/02/2020

Solicitante:

AC IMMUNE SA [CH]
GENENTECH INC [US]

US_2018327485_A1

Resumen de: US2020055928A1

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.

traducir

Protein-based therapy and diagnosis of tau-medicated pathology in Alzheimer's disease

NºPublicación: AU2020200624A1 20/02/2020

Solicitante:

AXON NEUROSCIENCE SE

CN_109265543_A

Resumen de: AU2020200624A1

H:\nterwoven\NRPortbl\DCC\FMT\19805074 _.docx-29/01/2020 The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

traducir

ANTI-PHF-TAU ANTIBODIES AND USES THEREOF

NºPublicación: CN110799531A 14/02/2020

Solicitante:

\u8A79\u68EE\u751F\u7269\u79D1\u6280\u516C\u53F8

KR_20190130133_A

Resumen de: US2018265575A1

Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

traducir

METHOD OF DIAGNOSING AND TREATING ALZHEIMER DISEASE USING PLASMA TAU LEVEL IN CONJUNT ION WITH BETA-AMYLOID LEVEL AS DIAGNOSTIC INDEX

NºPublicación: WO2020031116A1 13/02/2020

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]

Resumen de: WO2020031116A1

The present invention concerns correlation between plasma t-tau, p-tau and Aβ1-42 levels and AD-associated tau pathology in brain. The present invention also relates to methods for determining a level of brain tau accumulation in a brain region of a subject, diagnosing a tau positive subject and treating the same, assessing a progression of a sign or a symptom of Alzheimer disease and treating the same, detecting a sign or a symptom of Alzheimer disease in a subject and treating the same, determining brain glucose metabolism in a subject, determining a neurodegeneration level in a subject, and determining cognitive function in a subject, and diagnostic kits for determining a tau positive patient, diagnosing a tau positive subject or detecting a sign or a symptom of Alzheimer disease in a subject.

traducir

METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S) AND/OR NITROSO-REDOX STRESS SCAVENGER COMPOUND(S)

NºPublicación: US2020049718A1 13/02/2020

Solicitante:

PASTEUR INSTITUT [FR]
CENTRE NAT RECH SCIENT [FR]
COMMISSARIAT ENERGIE ATOMIQUE [FR]

US_2017242034_A1

Resumen de: US2020049718A1

The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated. The invention also relates to kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) having relevance for the symptoms discussed herein.

traducir

DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE

NºPublicación: WO2020032027A1 13/02/2020

Solicitante:

SUMITOMO DAINIPPON PHARMA CO LTD [JP]

Resumen de: WO2020032027A1

The present invention provides a polypeptide comprising any of the following amino acid sequences that are useful for diagnosing Alzheimer's disease: (1) an amino acid sequence expressed by SEQ ID NO: 1; or (2) an amino acid sequence in which one or several amino acids of the amino acid sequence expressed by SEQ ID NO:1 are substituted, deleted, added or inserted.

traducir

HCBI, MSBI, MSSI AND CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES

NºPublicación: EP3608425A1 12/02/2020

Solicitante:

DEUTSCHES KREBSFORSCH [DE]

JP_2019141042_A

Resumen de: EP3608425A1

Described are HCBI (Healthy Cattle Blood Isolate), MSBI (Multiple Sclerosis Brain Isolate), MSSI (Multiple Sclerosis Serum Isolate) and CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.

traducir

COMPOSITION FOR DIAGNOSING ALZHEIMER'S DISEASE BY USING ALTERATION OF CPG METHYLATION IN PROMOTER OF IDE GENE IN SKIN CELLS, AND USE THEREOF

NºPublicación: WO2020027569A1 06/02/2020

Solicitante:

EWHA UNIV INDUSTRY COLLABORATION FOUNDATION [KR]

KR_101965380_B1

Resumen de: WO2020027569A1

The present invention relates to a composition, a kit and a method, which are for diagnosing Alzheimer's disease by detecting the methylation level of CpG sites of an insulin degrading enzyme (IDE) gene promoter.

traducir

SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS

NºPublicación: WO2020028348A1 06/02/2020

Solicitante:

ALZHEON INC [US]

Resumen de: WO2020028348A1

Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid- like aggregates, e.g., Alzheimer's disease.

traducir

ANTI-EMAP II ANTIBODY AND USE THEREOF

NºPublicación: US2020040071A1 06/02/2020

Solicitante:

L&K BIOMED CO LTD [KR]

EP_3604336_A1

Resumen de: US2020040071A1

The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-α-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-α-mediated disease more effectively.

traducir

SYSTEM AND METHOD FOR MULTI-PARAMETER SPECTROSCOPY

NºPublicación: US2020041410A1 06/02/2020

Solicitante:

NXGEN PARTNERS IP LLC [US]

US_2019128808_A1

Resumen de: US2020041410A1

An apparatus for detecting material within a sample includes a light emitting unit for directing at least one light beam through the sample. The at least one light beam has a unique signature combination associated therewith responsive to passing through the sample. A Raman spectroscopic unit receives the at least one light beam that has passed through the sample and performs a Raman spectroscopic analysis to detect a first signature associated with the sample. An infrared spectroscopic unit receives the at least one light beam that has passed through the sample and performs an infrared spectroscopic analysis to detect a second signature associated with the sample. A database includes a plurality of unique combinations of the first signature and the second signature. Each of the plurality of unique combinations of the first signature and the second signature are associated with a particular material. A processor detects the material within the sample responsive to a comparison of a unique combination of the first signature and the second signature detected by the Raman spectroscopic unit and the infrared spectroscopic unit with the plurality of unique combinations of first signature and second signature within the database and determines a matching unique combination of the first signature and the second signature within the database, wherein identification of the unique combination of the first signature and the second signature enables detection of the material not detectab

traducir

ANTIBODIES TO TAU

NºPublicación: KR20200013072A 05/02/2020

Solicitante:

\uC6CC\uC2F1\uD134 \uC720\uB2C8\uBC84\uC2DC\uD2F0

JP_2018184398_A

Resumen de: WO2014008404A1

This invention relates to antibodies to tau and methods of use thereof.

traducir

BINDING MOLECULES THAT SPECIFICALLY BIND TO TAU

NºPublicación: EP3601335A1 05/02/2020

Solicitante:

JANSSEN VACCINES & PREVENTION BV [NL]

KR_20190133191_A

Resumen de: WO2018178077A1

The invention relates to binding molecules and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using the binding molecules or antigen-binding fragments.

traducir

NEW TAU SPECIES

NºPublicación: EP3601325A1 05/02/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV DE LILLE [FR]
CENTRE HOSPITALIER REGIONAL UNIV DE LILLE [FR]
CENTRE NAT RECH SCIENT [FR]
ECOLE SUPERIEURE PHYSIQUE & CHIMIE IND VILLE DE PARIS [FR]

US_2020031891_A1

Resumen de: WO2018178078A1

The invention relates to the identification of a new Tau species starting at residue Met11 (Met11-Tau) which is N-alpha-terminally acetylated form (N-alpha-acetyl-Met11-Tau species: Ac-Met11-Tau). Several monoclonal antibodies specific of this new Tau species have been developed. One of this antibody, 2H2/D11, was used in THY-Tau22 mouse model (that develops with age neurofibrillary degeneration (NFD) and memory deficits), and N-alpha- Ac-Met11-Tau species were clearly detected early in neurons displaying NFD on hippocampal brain sections while it is not reactive in hippocampus from elderly controls. Finally, by using ELISA sandwich specific of Ac-Met11-Tau species, Alzheimer Disease (AD) brain samples are clearly discriminated from human elderly control brains. Thus the invention relates to this new Tau species starting from the methionine residue at position 11 said methionine being N-alpha acetylated. The invention also relates to antibody that specifically binds this new tau species, a method of detection of this new Tau species and a method of diagnosis of Tauopathy disorder.

traducir

LYMPHOCYTE-BASED MORPHOMETRIC TEST FOR ALZHEIMER'S DISEASE

NºPublicación: EP3600027A1 05/02/2020

Solicitante:

NEURODIAGNOSTICS LLC [US]

KR_20190132466_A

Resumen de: US2018284103A1

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.

traducir

LYMPHOCYTE-BASED PKCe TEST FOR ALZHEIMER'S DISEASE

NºPublicación: EP3601601A1 05/02/2020

Solicitante:

NEURODIAGNOSTICS LLC [US]

WO_2018183669_A1

Resumen de: US2018282784A1

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods involve the steps of (a) culturing lymphocytes from the subject under suitable conditions; (b) measuring the amount of PKCϵ in the cultured lymphocytes; and (c) comparing the measurement of step (b) with a suitable control.

traducir

ANTI-EMAP II ANTIBODY AND USE THEREOF

NºPublicación: EP3604336A1 05/02/2020

Solicitante:

L&K BIOMED CO LTD [KR]

US_2020040071_A1

Resumen de: EP3604336A1

The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-α-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-α-mediated disease more effectively.

traducir

Antibodies to tau

NºPublicación: NZ739622A 31/01/2020

Solicitante:

UNIV WASHINGTON

KR_20200013072_A

Resumen de: NZ739622A

This invention relates to antibodies to tau and methods of use thereof, particularly to isolated monoclonal antibodies specifically binding tau and capable of reducing tau aggregation.

traducir

GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS.

NºPublicación: IL230061A 30/01/2020

Solicitante:

UNIV INDIANA RES & TECH CORP [US]

US_2019127433_A1

Resumen de: MX2013015176A

Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.

traducir

EDITING PROFILING OF PDE8A PRE -MRNA: USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS

NºPublicación: US2020032338A1 30/01/2020

Solicitante:

ALCEDIAG [FR]

US_2018010184_A1

Resumen de: US2020032338A1

The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.

traducir

NEW TAU SPECIES

NºPublicación: US2020031891A1 30/01/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV DE LILLE [FR]
CENTRE HOSPITALIER REGIONAL UNIV DE LILLE [FR]
CENTRE NAT RECH SCIENT [FR]
ECOLE SUPERIEURE PHYSIQUE & CHIMIE IND VILLE DE PARIS [FR]

WO_2018178078_A1

Resumen de: US2020031891A1

The invention relates to the identification of a new Tau species starting at residue Met11 (Met11-Tau) which is N-alpha-terminally acetylated form (N-alpha-acetyl-Met11-Tau species: Ac-Met11-Tau). Several monoclonal antibodies specific of this new Tau species have been developed. One of this antibody, 2H2/D11, was used in THY-Tau22 mouse model (that develops with age neurofibrillary degeneration (NFD) and memory deficits), and N-alpha-Ac-Met11-Tau species were clearly detected early in neurons displaying NFD on hippocampal brain sections while it is not reactive in hippocampus from elderly controls. Finally, by using ELISA sandwich specific of Ac-Met11-Tau species, Alzheimer Disease (AD) brain samples are clearly discriminated from human elderly control brains. Thus the invention relates to this new Tau species starting from the methionine residue at position 11 said methionine being N-alpha acetylated. The invention also relates to antibody that specifically binds this new tau species, a method of detection of this new Tau species and a method of diagnosis of Tauopathy disorder.

traducir

MONOCLONAL ANTIBODIES AGAINST A PEPTIDE REGULATING THE SYNTHESIS OF PSEN 1 PROTEIN ASSOCIATED WITH ALZHEIMER'S DISEASE

NºPublicación: LT2018534A 27/01/2020

Solicitante:

VILNIAUS UNIV [LT]

Resumen de: LT2018534A

The present invention provides novel monoclonal antibodies specific for the PSEN1-49 peptide encoded by the human PSEN1 gene. The developed monoclonal antibodies can be used for diagnostic purposes. The present invention provides novel hybridomas 11D1 and 2C1 that produce monoclonal antibodies against the 49 amino acid peptide PSEN1-49 encoded by the 5'-NCS of the PSEN1 gene. Detailed analysis of the recognition sequences showed that 11D1 and 2C1 monoclonal antibodies recognize different fragments of the PSEN1 sequence. Monoclonal antibodies can be used to test the PSEN1-49 peptide and to develop assay kits.

traducir

A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF

Nº publicación: US2020022343A1 23/01/2020

Solicitante:

THE JACKSON LABORATORY [US]
UNIV INDIANA RES & TECH CORP [US]

CA_3057289_A1

Resumen de: US2020022343A1

Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

traducir

Página1 de 3 nextPage por página

punteroimgVolver